secwatch.observer — SEC 8-K summary
======================================

Issuer:     Artiva Biotherapeutics, Inc. (ARTV)
CIK:        0001817241
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001193125-26-213239
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artiva reports 71% ACR50 in refractory RA at 6 months, FDA alignment for Phase 3 trial; Q1 net loss $23.5M
--------------------------------------------------------------------------------

- 71% ACR50 response in company-sponsored Phase 2a at 6 months (5/7 patients); no relapses or new immunomodulatory agents.
- FDA aligned on single Phase 3 registrational trial for AlloNK in ~150 refractory RA patients; ACR50 at 6 months primary endpoint.
- Safety: no CRS, ICANS, or AlloNK-related discontinuations; outpatient administration in community rheumatology clinics.
- Q1 net loss $23.5M; cash $86.8M expected to fund operations into Q2 2027.
- ATM sales suspended under Sales Agreement with Leerink; agreement remains in effect.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817241/000119312526213239/0001193125-26-213239-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817241/000119312526213239/d38160d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-213239

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer